Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

AI: the smart money is on the smart thinking

Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials

- PMLiVE

The blurred lines between sepsis and COVID-19

This week, the UK Sepsis Trust (UKST) launched a new health communications campaign to raise awareness of the relationship between COVID-19 and sepsis, and to offer patient support to those...

11 London

Porterhouse Medical Group

Porterhouse Medical Group joins imc group

Agency will be a key addition to imc's growing network of international offices

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

- PMLiVE

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival

- PMLiVE

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Deal includes portfolio of small molecule LRRK2 inhibitors

- PMLiVE

Socially distanced strategising

The new normal can improve how you create strategy

Artificial Intelligence in Digital Therapeutics

Leo Grady, CEO of Paige.AI uncovers what it has been like being a pioneer in the digital therapeutic space and the many challenges that come with bringing AI technology to market....

Impetus Digital

Virtual Reality in Medicine and Clinical Research

In the latest episode of Impetus Digital's Fireside Chat, I sit down with Ville Leppälä, Vertical Lead, Research and Medical, at Varjo. We discuss the potential applications of virtual reality, augmented...

Impetus Digital

- PMLiVE

Novartis builds its case for novel MS treatment ofatumumab

Detailed results from phase 3 studies published in NEJM

- PMLiVE

J&J inks $1bn deal with US for coronavirus vaccine

Agreement includes manufacturing and delivery of 100 million doses

- PMLiVE

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

ALK inhibitor improved progression-free survival in first-line setting

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links